Abstract:Objective: To observe the clinical efficacy and safety of ultrasound-guided intra-articular injection of methylene blue in the treatment of lumbar facet joint syndrome(LFJS). Methods: 120 patients with LFJS were randomly divided into methylene blue group (MB group) and steroids group (Control group). Numeric Rating Scales (NRS), Oswestry Disability Index (ODI), Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9(PHQ-9) were evaluated preoperation and after operation, and adverse events were recorded. Results: The NRS scores of the methylene blue group was slightly lower than that of the control group at 1 week and 1 month after operation, but it was significantly better than control group at 3 months and 6 months (P < 0.05). The ODI, PHQ-9, and PSQI scores of the MB group significantly decreased at 6 months (P < 0.05). As for clinical efficacy, the MB group was better than control group(P < 0.05). On the first day after operation, the incidence of hyperglycemia in patients with diabetes in the MB group was significantly lower than that of the control group(P < 0.05), and other adverse reactions (hypertension, nausea and vomiting) with no significant difference. Conclusion: Ultrasound-guided intra-articular injection of methylene blue can significantly relieve the symptoms of patients with LFJS, improve the function and enhance the quality of life, with less adverse reactions and more safety.